Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Circulating tumour DNA analysis to predict and monitor minimal residual disease in breast cancer patients undergoing neoadjuvant treatment

FY 2020-21

Summary
Breast cancer is the second most diagnosed cancer in Canada, with 27,700 Canadians expected to be diagnosed in 2020. Despite recent progress in breast cancer survival rates, about 20 percent of patients relapse and die from metastatic disease. Many of these deaths are caused by undetectable metastases present at diagnosis that persist following therapy, over time leading to incurable metastatic relapse. Therefore, further advances in reducing breast cancer mortality require better methods to identify which patients have minimal residual disease (MRD) following standard therapy. This would allow for stratification of high-risk patients who may benefit from additional treatment while sparing low-risk patients from unnecessary side effects of overtreatment. Many studies have shown that the detection of circulating tumour DNA (ctDNA) may be used to detect MRD in early breast cancer patients. ctDNA are cell-free DNA fragments released into circulation when tumour cells die. ctDNA contains cancer-specific genetic and epigenetic alterations, enabling its use as a minimally invasive biomarker through liquid biopsy. Our research will characterize an optimal ctDNA test to detect and monitor MRD in high-risk early breast cancer patients following therapy, with the ultimate goal of finding accurate predictors of relapse and treatment response. We will assess the tests in serial samples from patients with high-risk early breast cancer collected throughout therapy and follow-up. This research will help precise risk assessment and development of intervention strategies to enable more effective treatment decisions and prevent relapse in breast cancer patients. Overall, our work has the potential to directly impact the care of breast cancer patients and improve their survival outcomes.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449840
Name
Main Sasha C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Circulating tumour DNA analysis to predict and monitor minimal residual disease in breast cancer patients undergoing neoadjuvant treatment
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Capp-Seq; Cell-Free Dna; Cfmedip-Seq; Circulating Tumour Dna; Liquid Biopsy; Minimal Residual Disease; Novel Biomarkers
Abstract
Breast cancer is the second most diagnosed cancer in Canada, with 27,700 Canadians expected to be diagnosed in 2020. Despite recent progress in breast cancer survival rates, about 20 percent of patients relapse and die from metastatic disease. Many of these deaths are caused by undetectable metastases present at diagnosis that persist following therapy, over time leading to incurable metastatic relapse. Therefore, further advances in reducing breast cancer mortality require better methods to identify which patients have minimal residual disease (MRD) following standard therapy. This would allow for stratification of high-risk patients who may benefit from additional treatment while sparing low-risk patients from unnecessary side effects of overtreatment. Many studies have shown that the detection of circulating tumour DNA (ctDNA) may be used to detect MRD in early breast cancer patients. ctDNA are cell-free DNA fragments released into circulation when tumour cells die. ctDNA contains cancer-specific genetic and epigenetic alterations, enabling its use as a minimally invasive biomarker through liquid biopsy. Our research will characterize an optimal ctDNA test to detect and monitor MRD in high-risk early breast cancer patients following therapy, with the ultimate goal of finding accurate predictors of relapse and treatment response. We will assess the tests in serial samples from patients with high-risk early breast cancer collected throughout therapy and follow-up. This research will help precise risk assessment and development of intervention strategies to enable more effective treatment decisions and prevent relapse in breast cancer patients. Overall, our work has the potential to directly impact the care of breast cancer patients and improve their survival outcomes.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Main, Sasha C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~